COVID-19

8 July, 2020

Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis

2024-03-29T13:31:59+03:00By hiss|Categories: Pathogenesis, Publications|Tags: Anakinra, COVID-19|

George Dimopoulos, Quirijn de Mast, Nikolaos Markou, Maria Theodorakopoulou, Apostolos Komnos, Maria Mouktaroudi, Mihai G Netea, Themistoklis Spyridopoulos, Rebecca J Verheggen, Jacobien Hoogerwerf, Alexandra Lachana, Frank L van de Veerdonk, Evangelos J. Giamarellos-Bourboulis Cell Host & Microbe 2020 Jul 8;28(1):117-123.e1 DOI 10.1016/j.chom.2020.05.007Download pdf 🡇 Funding The study was funded in part by the

1 June, 2020

Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure

2024-04-01T07:03:28+03:00By hiss|Categories: Pathogenesis, Publications|Tags: COVID-19|

Evangelos J. Giamarellos-Bourboulis, Mihai G Netea, Nikoletta Rovina, Karolina Akinosoglou, Anastasia Antoniadou, Nikolaos Antonakos, Georgia Damoraki, Theologia Gkavogianni, Maria-Evangelia Adami, Paraskevi Katsaounou, Maria Ntaganou, Magdalini Kyriakopoulou, George Dimopoulos, Ioannis Koutsodimitropoulos, Dimitrios Velissaris, Panagiotis Koufargyris, Athanassios Karageorgos, Konstantina Katrini, Vasileios Lekakis, Mihaela Lupse, Antigone Kotsaki, George Renieris, Danai Theodoulou, Vassiliki Panou, Evangelia Koukaki, Nikolaos Koulouris,

1 June, 2020

ACTIVATE-II

2023-01-09T12:12:57+03:00By hiss|Categories: Completed, Interventional, Sepsis and severe infections, Studies|Tags: BCG, COVID-19|

Completed study Official Study Title A randomized clinical trial for enhanced trained immune responses through Bacillus Calmette-Guérin vaccination to prevent infections by COVID-19 Brief Description ACTIVATE-II is a randomized clinical trial aiming to investigate if the developing concept of trained immunity i.e. the memory of the innate immune system coming after vaccination exists in

28 May, 2020

Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection

2023-02-16T14:28:59+03:00By hiss|Categories: Publications|Tags: COVID-19|

Mihai G Netea, Evangelos J. Giamarellos-Bourboulis, Jorge Domínguez-Andrés, Nigel Curtis, Reinout van Crevel, Frank L van de Veerdonk, Marc Bonten Cell 2020 May 28;181(5):969-977 DOI 10.1016/j.cell.2020.04.042 View article 🡇 Funding M.G.N. was supported by an ERC advanced grant (833247) and a Spinoza grant of the Netherlands Association for Scientific Research.

1 May, 2020

ACHIEVE

2023-01-09T12:17:31+03:00By hiss|Categories: Completed, Interventional, Sepsis and severe infections, Studies|Tags: clarithromycin, COVID-19|

Completed study Official Study Title Anti-inflammatory ClaritHromycin to ImprovE SARS-CoV-2 (COVID-19) infection Early: The ACHIEVE open-label non-randomized clinical trial Brief Description ACHIEVE is an open non-randomized clinical trial aiming to prove that the addition of oral clarithromycin to treatment regimen of COVID-19 is associated with early clinical improvement and attenuation of the high inflammatory

30 April, 2020

Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia

2023-02-16T14:29:21+03:00By hiss|Categories: Biomarkers, Publications|Tags: COVID-19, suPAR|

Nikoletta Rovina, Karolina Akinosoglou, Jesper Eugen-Olsen, Salim Hayek, Jochen Reiser, Evangelos J. Giamarellos-Bourboulis Critical Care 2020 Apr 30;24(1):187 DOI: 10.1186/s13054-020-02897-4View article 🡇 Funding The study was funded by unrestricted educational grants provided by the Hellenic Institute for the Study of Sepsis. Funds were also provided by Rush University Medical Center. Keywords: COVID-19;

1 April, 2020

SAVE

2024-10-18T12:29:07+03:00By hiss|Categories: Completed, Interventional, Sepsis and severe infections, Studies|Tags: Anakinra, COVID-19|

Completed study Official Study Title suPAR-guided Anakinra treatment for Validation of the risk and Early management of severe respiratory failure by COVID-19: the SAVE open-label, non-randomized single-arm trial Brief Description SAVE is an open non-randomized clinical trial aiming to study the early treatment of patients with COVID-19 pneumonia with anakinra guided by the biomarker

1 April, 2020

ESCAPE

2023-01-09T12:13:22+03:00By hiss|Categories: Completed, Interventional, Sepsis and severe infections, Studies|Tags: Anakinra, COVID-19|

Completed study Official Study Title Efficiency in management of organ dysfunction associated with infection by the novel SARS-Cov-2 virus through A PErsonalized immunotherapy approach Brief Description ESCAPE is an open non-randomized clinical trial aiming to the personalized therapy of patients with COVID-19. Using biomarkers, enrolled patients are receiving treatment with intravenous anakinra or intravenous

1 November, 2019

PROUD-1

2023-01-09T12:14:18+03:00By hiss|Categories: Completed, Interventional, Sepsis and severe infections, Studies|Tags: COVID-19, Sepsis|

Completed study Official Study Title Pulse PhotoplethysmogAaphy as an early tool for the diagnosis of sepsis thrOUgh a two-stage Development approach Brief Description PROUD-1 is an interventional trial aiming to validate the diagnostic accuracy of a new optical biosensor for the diagnosis of sepsis and for COVID-19. Details Status: Completed Study Type: Interventional